Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

172 comunicati stampa

Guarda tutti i comunicati
17/12/2025
Analisi di mercato
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
12/12/2025
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
04/12/2025
Industria
Veterinaria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
26/11/2025
Biotecnologia
Farmaceutica
Salute
Eventi
Web e Social Network
Merck to Participate in the Citi 2025 Global Healthcare Conference
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Eventi
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
21/11/2025
Industria
Biotecnologia
Farmaceutica
Medicina - Varie
Oncologia
Sanità
Salute
Igiene alimentare
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Titoli e azioni
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Scienza
Farmaceutica
Biotecnologia
Merck Announces First-Quarter 2026 Dividend
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
18/11/2025
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Industria
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0